natgillin/translations-raw huggingface dataset:
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tasermity, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
For more information about treatment with Tasermity, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Tasermity preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
For the full list of all side effects and restrictions with Tasermity, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Tasermity glejte navodilo za uporabo.
It is not intended to provide practical advice on how to use Tasermity. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
It can be used in patients undergoing haemodialysis (using a blood filtration machine) or peritoneal dialysis (where fluid is pumped into the abdomen and an internal body membrane filters the blood). 
Lahko se uporablja pri bolnikih, ki potrebujejo hemodializo (z uporabo naprave za filtriranje krvi) ali peritonealno dializo (pri kateri se tekočina črpa v trebuh, notranja telesna membrana pa filtrira kri).
For practical information about using Tasermity, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Tasermity naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Studies have shown that Tasermity significantly reduces blood phosphate levels in patients with kidney disease undergoing dialysis. 
Študije so pokazale, da zdravilo Tasermity pomembno zniža ravni fosfatov v krvi pri bolnikih z obolenjem ledvic, ki potrebujejo dializo.
When taken with meals, the sevelamer molecules in Tasermity attach in the gut to phosphate from food, preventing it from being absorbed into the body. 
Ko se zdravilo Tasermity vzame ob obroku, se molekule sevelamerja iz njega vežejo na fosfate iz hrane v prebavilih in s tem preprečijo, da bi se absorbirali v telo.
Similar results with Tasermity were seen in another 8-week study involving 172 haemodialysis patients, while in a third longer-term study (over 44 weeks) Tasermity led to an average fall of 0.71 mmol/l. 
Podobne rezultate pri uporabi zdravila Tasermity so zabeležili tudi v drugi osemtedenski študiji, v kateri je sodelovalo 172 bolnikov na hemodializi, v tretji dolgoročnejši študiji (ki je trajala več kot 44 tednov) pa je zdravilo Tasermity v povprečju znižalo ravni fosfatov za 0,71 mmol/l.
Why is Tasermity approved? 
Zakaj je bilo zdravilo Tasermity odobreno?
The benefit of Tasermity has also been shown in a study of 143 patients undergoing peritoneal dialysis: patients receiving Tasermity in this study had similar falls in phosphate levels over 12 weeks as the patients receiving calcium acetate (0.52 and 0.58 mmol/l, respectively). 
Zdravilo Tasermity je izkazalo koristi tudi v študiji, v kateri je sodelovalo 143 bolnikov na peritonealni dializi: pri bolnikih, ki so v tej študiji prejemali zdravilo Tasermity, so v 12 tednih zabeležili podobno znižanje ravni fosfatov kot pri bolnikih, ki so prejemali kalcijev acetat (0,52 oziroma 0,58 mmol/l).
In a study of 84 patients undergoing haemodialysis, there was an average fall in phosphate levels of 0.65 mmol/l in patients taking Tasermity for 8 weeks, compared with a fall of 0.68 mmol/l in patients taking calcium acetate, another phosphate-lowering medicine. 
V študiji, v kateri je sodelovalo 84 bolnikov na hemodializi, so se ravni fosfatov pri bolnikih, ki so osem tednov jemali zdravilo Tasermity, v povprečju znižale za 0,65 mmol/l, pri bolnikih, ki so jemali drugo zdravilo za zniževanje ravni fosfatov, kalcijev acetat, pa za 0,68 mmol/l.
Tasermity is a medicine used to control hyperphosphataemia (high blood phosphate levels) in adult patients on dialysis (a blood clearance technique). 
Tasermity je zdravilo, ki se uporablja za uravnavanje hiperfosfatemije (visokih ravni fosfatov v krvi) pri odraslih bolnikih na dializi (tehnika čiščenja krvi).
Tasermity must not be used in people with hypophosphataemia (low blood phosphate levels) or with bowel obstruction (a blockage in the gut). 
Zdravilo Tasermity se ne sme uporabljati pri ljudeh s hipofosfatemijo (nizkimi ravnmi fosfatov v krvi) ali črevesno obstrukcijo (zaporo črevesja).
The active substance in Tasermity, sevelamer hydrochloride, is a phosphate binder. 
Zdravilna učinkovina v zdravilu Tasermity, sevelamerijev klorid, je fosfatni vezalec.
How does Tasermity work? 
Kako zdravilo Tasermity deluje?
How is Tasermity used? 
Kako se zdravilo Tasermity uporablja?
Tasermity sevelamer hydrochloride 
Tasermity sevelamerijev klorid
Tasermity contains the active substance sevelamer hydrochloride. 
Zdravilo Tasermity vsebuje zdravilno učinkovino sevelamerijev klorid.
2 to 4 GBq per vial at calibration date 
2 till 4 GBq per injektionsflaska vid kalibreringsdatum
EU Number Invented name Strength 
Izmišljeno ime Jakost
1.5 - 3.1 ml 1 vial 
Raztopina za injiciranje Intravenska uporaba Viala (steklo) 1,5 ml - 3,1 ml
Intravenous use 
Ovojnina
Pharmaceutical form Route of administration Packaging Content 
Farmacevtska oblika Način uporabe
Vial (glass) 
1 viala
Date of first authorisation: 11 March 2010 Date of latest renewal: 15 January 2015 
Datum prve odobritve: 11. marec 2010 Datum zadnjega podaljšanja: 15. januar 2015
• persistent for ≥4 weeks, or 
• so persistentne in trajajo ≥4 tedne, ali
% patients achieving virologic response 
% bolnikov, ki so dosegli virološki odziv
Do not take more than one dose of Revolade in one day. 
Ne vzemite več kot enega odmerka zdravila Revolade v enem dnevu.
Now you need to complete steps 11 to 13 to make sure the child receives all of the medicine. 
Zdaj morate izvesti korake 11 do 13 in s tem zagotoviti, da otrok prejme celoten odmerek zdravila.
Make sure the child has time to swallow. 
Pazite, da bo imel otrok čas za požiranje.
Don't drive or use machines unless you are sure you're not affected. 
Ne vozite ali upravljajte s stroji, razen, če ste prepričani, da vaša sposobnost ni prizadeta.
Method of administration (see section 6.6) 
Način uporabe (glejte poglavje 6.6)
You have now given the child nearly all of their dose of medicine. 
Tako ste dali otroku skoraj celoten odmerek zdravila.
• Prepare the suspension with water only. 
• Suspenzijo pripravljajte samo z vodo.
Table 4 Secondary efficacy results from RAISE 
Preglednica 4 Rezultati sekundarne učinkovitosti iz študije RAISE
IMPORTANT: 
POMEMBNO:
Patients received study medication for up to 8 years (in EXTEND). 
Bolniki so študijsko zdravilo prejemali do 8 let (v študiji EXTEND).
The majority of TEEs were non-serious and resolved by the end of the study. 
Večina trombemboličnih dogodkov ni bilo resnih in so se razrešili do konca študije.
... and for 2 hours after 
... in 2 uri po zaužitju
Again fill the syringe, this time with 10 ml of drinking water. 
Ponovno napolnite brizgo, vendar tokrat samo z 10 ml pitne vode.
• Administer the oral suspension immediately after preparation. 
• Peroralno suspenzijo je treba uporabiti takoj po pripravi.
If treatment is considered clinically indicated, close monitoring of these patients is required. 
Če je zdravljenje klinično indicirano, je potrebno skrbno spremljanje teh bolnikov.
The clinical significance of these QTc prolongation events is unknown. 
Klinični pomen teh dogodkov podaljšanja QTc ni znan.
<50,000/µl following at least 2 weeks of therapy 
<50.000/µl po najmanj 2 tednih zdravljenja
This was measured by delayed phototoxic index. 
To je bilo ovrednoteno z indeksom zakasnele fototoksičnosti.
For more advice about suitable foods and drinks, talk to your doctor. 
Za več nasvetov o primerni prehrani in pijači se posvetujte z zdravnikom.
This includes medicines obtained without prescription and vitamins. 
To vključuje tudi zdravila, ki jih lahko dobite brez zdravniškega recepta, in vitamine.
QT/QTc prolongation 
Podaljšanje QT/QTc
If your doctor considers that the benefits of taking Revolade outweigh the risks, you will be closely monitored during treatment. 
Če vaš zdravnik meni, da koristi jemanja zdravila Revolade presegajo tveganja, vas bo med zdravljenjem skrbno spremljal.
• Wash your hands with soap and water. 
• Roke si umijte z milom in vodo.
Avoid direct contact with the medicine. 
Izogibajte se neposrednemu stiku z zdravilom.
Older people (65 years and above) 
Starejši ljudje (stari 65 let ali več)
• progressive, or 
• so progresivne, ali
Juvenile animal studies 
Študije na živalskih mladičih
Hepatic decompensation (use with interferon) 
Jetrna dekompenzacija (uporaba z interferonom)
It is important to tell a doctor if you develop these symptoms. 
Pomembno je, da poveste zdravniku, če se pri vas pojavijo ti simptomi.
Revolade with food and drink 
Zdravilo Revolade skupaj s hrano in pijačo
Make sure that 
Poskrbite, da
EXP Use within 30 minutes of reconstitution. 
EXP Zdravilo uporabite v 30 minutah po rekonstituciji.
What Revolade is and what it is used for 
Kaj je zdravilo Revolade in za kaj ga uporabljamo
These in vitro and in vivo findings suggest that eltrombopag does not pose a genotoxic risk to humans. 
Te in vitro ter in vivo ugotovitve kažejo, da eltrombopag ne predstavlja genotoksičnega tveganja za človeka.
But there will still be some left in the bottle, even though you may not be able to see it. 
Nekaj zdravila pa še vedno ostane na dnu plastenke, čeprav ga morda ne vidite.
The effect of Revolade during pregnancy is not known. 
Učinek zdravila Revolade med nosečnostjo ni znan.
Eltrombopag is highly bound to human plasma proteins (>99.9%), predominantly to albumin. 
Eltrombopag se v obsežni meri veže na humane plazemske proteine (>99,9 %), predvsem na albumin.
Effects were less severe at lower doses and were characterised by a spectrum of regenerative changes. 
Pri uporabi manjših odmerkov so bili učinki blažji, zanje pa je bil značilen spekter regenerativnih sprememb.
• if you have another blood condition, such as myelodysplastic syndrome (MDS). 
• če imate kakšno drugo bolezen krvi, kot je mielodisplastični sindrom (MDS).
Eltrombopag has negligible influence on the ability to drive and use machines. 
Eltrombopag ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
• some medicines to treat HIV infection, such as lopinavir and/or ritonavir 
• nekatera zdravila za zdravljenje okužb s HIV, kot je lopinavir in/ali ritonavir.
Table 5 Efficacy results from TRA100773B 
Preglednica 5 Rezultati učinkovitosti iz študije TRA100773B
You will need regular tests 
Potrebne redne preiskave
The plasma elimination half-life of eltrombopag is approximately 21-32 hours. 
Plazemski razpolovni čas izločanja eltrombopaga znaša približno 21-32 ur.
Your doctor may consider it necessary to monitor your heart during treatment with Revolade and carry out an electrocardiogram (ECG) test. 
Zdravnik bo mogoče ocenil, da je potrebno spremljanje vaše srčne funkcije med zdravljenjem z zdravilom Revolade in vam bo posnel elektrokardiogram (EKG).
The majority of patients (84%) had received at least 2 prior immunosuppressive therapies. 
Večina bolnikov (84 %) je predhodno prejemala že najmanj 2 imunosupresivni zdravili.
Clinical studies comparing eltrombopag to other treatment options (e.g. splenectomy) have not been conducted. 
Kliničnih študij, ki bi primerjale eltrombopag z drugimi možnostmi zdravljenja (npr. splenektomijo), niso izvedli.
Do not change the dose or schedule for taking Revolade unless your doctor or pharmacist advises you to. 
Ne spreminjajte odmerka ali urnika jemanja zdravila Revolade, razen če vam tako svetuje vaš zdravnik ali farmacevt.
(The mixing bottle may become stained from the medicine. 
(Mešalna plastenka lahko ostane obarvana zaradi zdravila.
Before you start Read these messages first 
Preden začnete Najprej preberite spodnja opozorila
• Revolade powder must be mixed only with water at room temperature. 
• Prašek zdravila Revolade se sme mešati samo z vodo sobne temperature.
• accompanied by increased direct bilirubin, or 
• jih spremlja zvišanje vrednosti direktnega bilirubina, ali
• if you are allergic to eltrombopag or any of the other ingredients of this medicine (listed in section 6 under ‘What Revolade contains'). 
• če ste alergični na eltrombopag ali katero koli sestavino tega zdravila (navedeno v poglavju 6 »Kaj vsebuje zdravilo Revolade«).
Nevertheless, a potential risk of photoallergy cannot be ruled out since no specific preclinical study could be performed. 
Kljub temu pa možnega tveganja za pojav fotoalergijskih reakcij ni možno izključiti, saj specifičnih predkliničnih študij ni mogoče izvesti.
The relevance of this finding, as with other thrombopoietin receptor (TPO-R) agonists, has not been established yet. 
Pomen te ugotovitve, kot pri drugih agonistih trombopoetinskih receptorjev (TPO-R), še ni znan.
• IMPORTANT: Because some medicine will remain in the mixing bottle, complete the following steps. 
• POMEMBNO: Nekaj zdravila ostane v mešalni plastenki, zato morate izvesti še naslednja dva koraka.
The above warnings and precautions for ITP also apply to the paediatric population. 
Zgoraj nevedena opozorila in previdnostni ukrepi pri ITP veljajo tudi za pediatrično populacijo.
Absorption and bioavailability 
Absorpcija in biološka uporabnost
Total number of patients entering antiviral treatment phase n=956 n=485 n=450 n=232 n=506 n=253 
Celokupno število bolnikov, ki so vstopili v fazo protivirusnega zdravljenja n = 956 n = 485 n = 450 n = 232 n = 506 n = 253
Data are limited to 21 out of the planned 60 patients with haematological responses reported by 52% of patients at 6 months. 
Podatki so omejeni na 21 od načrtovanih 60 bolnikov s hematološkim odzivom, o katerem poročajo pri 52 % bolnikov v 6. mesecu zdravljenja.
If you have MDS and take Revolade, your MDS may get worse. 
Če imate MDS in jemljete zdravilo Revolade, se lahko vaš MDS poslabša.
What you need to know before you take Revolade 
Kaj morate vedeti, preden boste vzeli zdravilo Revolade
Double-blind placebo-controlled studies 
Dvojno slepe s placebom kontrolirane študije
Abnormal serum liver tests should be evaluated with repeat testing within 3 to 5 days. 
Nenormalne rezultate testov jetrne funkcije je treba ovrednotiti s ponovno preiskavo v 3 do 5 dneh.
Make sure that the bottle, cap and lid are dry before you use them. 
Poskrbite, da bodo plastenka, poklopec in zaporka suhi, preden jih boste uporabili.
• if you are at risk of blood clots in your veins or arteries, or you know that blood clots are common in your family. 
• če pri vas obstaja tveganje za pojav krvnih strdkov v venah ali arterijah ali veste, da je pojav krvnih strdkov pogost v vaši družini.
The studies consisted of two phases - a pre-antiviral treatment phase and an antiviral treatment phase. 
Študije so bile izvedene v dveh fazah - faza brez protivirusnega zdravljenja in faza protivirusnega zdravljenja.
Gently and slowly shake the mixing bottle backwards and forwards for at least 20 seconds to mix the water with the powder. 
Mešalno plastenko rahlo in počasi nagibajte naprej in nazaj najmanj 20 sekund, da boste vodo zmešali s praškom.
Table 7 Virologic response in HCV patients in ENABLE 1 and ENABLE 2 
Preglednica 7 Virološki odziv pri bolnikih s HCV pri ENABLE 1 in ENABLE 2
Side effects with frequency not known Frequency cannot be estimated from the available data 
Neželeni učinki z neznano pogostnostjo Njihove pogostnosti ni mogoče oceniti na osnovi razpoložljivih podatkov:
NO dairy products, antacids or mineral supplements 
Ne smete zaužiti mlečnih izdelkov, antacidov ali mineralnih prehranskih dopolnil
Component of a multipack, can't be sold separately. 
Del skupnega pakiranja, ni namenjen ločeni prodaji.
Repeat steps 7 to 10 - gently shake the bottle to mix the rest of the medicine, then give all the rest of the liquid to the child. 
Ponovite korake 7 do 10 - rahlo stresajte plastenko, da boste preostanek zdravila dobro premešali, nato pa otroku odmerite preostalo tekočino v celoti.
Do not take Revolade with dairy foods or drinks as the calcium in dairy products affects the absorption of the medicine. 
Zdravila Revolade ne smete jemati skupaj z živili ali pijačami mlečnega izvora, saj kalcij v mlečnih izdelkih vpliva na absorpcijo zdravila.
Other medicines and Revolade 
Druga zdravila in zdravilo Revolade
The powder for oral suspension is in sachets, the contents of which will need to mixed before you can take the medicine. 
Prašek za peroralno suspenzijo je pakiran v vrečicah, katerih vsebino je potrebno zmešati z vodo, preden lahko zdravilo zaužijete.
A QTc study in healthy volunteers dosed 150 mg eltrombopag per day did not show a clinically significant effect on cardiac repolarisation. 
QTc študija pri zdravih prostovoljcih, ki so prejemali 150 mg eltrombopaga na dan, ni pokazala klinično pomembnega učinka na srčno repolarizacijo.
Routine ophthalmologic monitoring of patients is recommended. 
Priporočljivo je rutinsko oftalmološko nadziranje bolnikov.
For more details on preparation and administration of the suspension, see Instructions for Use in the package leaflet. 
Za več podatkov o pripravi in odmerjanju suspenzije glejte Navodila za uporabo v priloženem navodilu za uporabo.
If you get a skin reaction, or if you have any questions, contact the doctor. 
Če pride do kožne reakcije ali če imate kakršnakoli vprašanja, pokličite zdravnika.
Progression of existing myelodysplastic syndrome (MDS) 
Napredovanje obstoječih mielodisplastičnih sindromov (MDS)
However a risk for humans cannot be ruled out (see section 5.3). 
Vendar nevarnosti pri ljudeh ne moremo izključiti (glejte poglavje 5.3).
Patients did not receive direct acting antiviral agents. 
Bolniki niso prejemali direktno delujočega protivirusnega zdravila.
ATC code: B02BX 05. 
oznaka ATC: B02BX05
Fill the syringe with the medicine. 
Brizgo napolnite z zdravilom.
• 1 clean glass or cup filled with drinking water (not supplied) 
• 1 čist kozarec ali skodelico pitne vode (nista priložena v kompletu)
After you have used all 30 sachets in the kit, dispose of the bottle. 
Ko boste porabili vseh 30 vrečic iz kompleta, zavrzite plastenko.
Overall SVR 
Celoten SVR
Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. 
V vsaki skupini po organskem sistemu so neželeni učinki razvrščeni po pogostnosti, pri čemer so najpogostejši učinki navedeni najprej.
ITP study population 
ITP študijska populacija
• confusion, agitation 
• zmedenost, agitacija
D-90429 Nuremberg Germany 
D-90429 Nuremberg Nemčija
Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out (see section 5.2). 
Druge klinične izkušnje, o katerih so poročali, ne kažejo na razlike v odzivu pri starostnikih in mlajših bolnikih, vendar pa večje občutljivosti posameznih starostnikov ni mogoče izključiti (glejte poglavje 5.2).
Loss of response to eltrombopag 
Izguba odziva na eltrombopag
Therefore, data from these animals do not fully model potential adverse effects related to the pharmacology of eltrombopag in humans, including the reproduction and carcinogenicity studies. 
Podatki, pridobljeni pri teh živalih, tako niso popoln model možnih neželenih učinkov, povezanih s farmakologijo eltrombopaga pri ljudeh, vključno s študijami vplivov na sposobnost razmnoževanja in kancerogenih učinkov.
Asian patients 
Bolniki azijskega porekla
Taking Revolade may make it easier for you to complete a full course of antiviral medicine (peginterferon and ribavirin). 
Jemanje zdravila Revolade vam bo olajšalo dokončanje celotnega zdravljenja s protivirusnimi zdravili (peginterferon in ribavarin).
The majority of patients were HCV genotype 1 (64%) and had bridging fibrosis/cirrhosis. 
Večina bolnikov je bila HCV genotip 1 (64 %) in je imela premostitveno fibrozo/cirozo.
Albumin levels f 
Vrednost albuminov f
• accumulation of iron in the body (iron overload) 
• kopičenje železa v telesu (preobremenitev z železom)
These findings were mostly mild (Grade 1-2), reversible and not accompanied by clinically significant symptoms that would indicate an impaired liver function. 
Zvišanja teh vrednosti so bila večinoma blaga (stopnja 1-2) in reverzibilna, brez klinično pomembnih simptomov, ki bi kazali na okvaro jetrne funkcije.
Dose adjustment or response 
Prilagoditev odmerka ali odziv
If you do, the medicine will not be properly absorbed into your body. 
V nasprotnem primeru absorpcija zdravila v telo ne bo popolna.
Many people with hepatitis C have low platelet counts, not only as a result of the disease, but also due to some of the antiviral medicines that are used to treat it. 
Številni ljudje s hepatitisom C imajo nizko število trombocitov, ne samo zaradi bolezni, ampak tudi zaradi nekaterih protivirusnih zdravil, ki se uporabljajo za zdravljenje teh okužb.
• dairy foods such as cheese, butter, yoghurt or ice cream 
• živil mlečnega izvora, kot so sir, maslo, jogurt ali sladoled.
Fertility was not affected in male or female rats at exposures that were comparable to those in humans. 
Plodnost ni bila prizadeta pri podganjih samcih in samicah pri izpostavljenosti, ki je bila primerljiva s tisto pri ljudeh.
Multilineage responses were reported by 45% of patients. 
O odzivu pri več linijah krvnih celic so poročali pri 45 % bolnikov.
Your doctor will recommend that you are checked for cataracts. 
Zdravnik vam bo priporočil, da opravite tudi preiskave za ugotovitev katarakte.
The median time on study to a cytogenetic abnormality was 2.9 months. 
Mediani čas v študiji do pojava citogenetske nepravilnosti je bil 2,9 meseca.
Some everyday medicines interact with Revolade - including prescription and non-prescription medicines and minerals. 
Nekatera vsakdanja zdravila vplivajo na delovanje zdravila Revolade - vključno z zdravili na recept in zdravili, ki jih lahko dobite brez recepta ter minerali.
Read and follow these instructions to prepare a dose of Revolade and give it to the child. 
Preberite spodnja navodila in jih upoštevajte pri pripravi odmerka zdravila Revolade, ki ga boste dali otroku.
Platelet counts >75,000/µl should be avoided. 
Potrebno se je izogibati številu trombocitov >75.000/µl.
ENABLE 1 utilised peginterferon alfa-2a plus ribavirin for antiviral treatment and ENABLE 2 utilised peginterferon alfa-2b plus ribavirin. 
Pri ENABLE 1 so uporabili peginterferon alfa-2a in ribavirin za protivirusno zdravljenje in pri ENABLE 2 so uporabili peginterferon alfa-2b in ribavirin.
The corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); not known (cannot be estimated from the available data). 
Pri tem ustrezna kategorija pogostnosti posameznega neželenega učinka temelji na naslednjem dogovoru (CIOMS III): zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Eltrombopag treatment should be initiated by and remain under the supervision of a physician who is experienced in the treatment of haematological diseases or the management of chronic hepatitis C and its complications. 
Zdravljenje z eltrombopagom je treba začeti in mora ostati pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem hematoloških bolezni ali kroničnih okužb s hepatitisom C in njegovih zapletov.
• disturbances of heart rhythm (QT prolongation) 
• motnje srčnega ritma (podaljšanje intervala QT)
• difficulty in sleeping (insomnia) 
• težave s spanjem (nespečnost)
You may choose to wear disposable gloves so your skin doesn't get stained. 
Če želite, si lahko nadenete rokavice za enkratno uporabo, da ne bi prišlo do obarvanja kože.
• liver injury due to medication 
• okvara jeter zaradi zdravil